<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34145402</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1473-1150</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>The pharmacogenomics journal</Title>
          <ISOAbbreviation>Pharmacogenomics J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes.</ArticleTitle>
        <Pagination>
          <StartPage>638</StartPage>
          <EndPage>648</EndPage>
          <MedlinePgn>638-648</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41397-021-00241-9</ELocationID>
        <Abstract>
          <AbstractText>Retinoids are widely used in diseases spanning from dermatological lesions to cancer, but exhibit severe adverse effects. A novel all-trans-Retinoic Acid (atRA)-spermine conjugate (termed RASP) has shown previously optimal in vitro and in vivo anti-inflammatory and anticancer efficacy, with undetectable teratogenic and toxic side-effects. To get insights, we treated HaCaT cells which resemble human epidermis with IC<sub>50</sub> concentration of RASP and analyzed their miRNA expression profile. Gene ontology analysis of their predicted targets indicated dynamic networks involved in cell proliferation, signal transduction and apoptosis. Furthermore, DNA microarrays analysis verified that RASP affects the expression of the same categories of genes. A protein-protein interaction map produced using the most significant common genes, revealed hub genes of nodal functions. We conclude that RASP is a synthetic retinoid derivative with improved properties, which possess the beneficial effects of retinoids without exhibiting side-effects and with potential beneficial effects against skin diseases including skin cancer.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Grafanaki</LastName>
            <ForeName>Katerina</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University Hospital of Patras, School of Medicine, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skeparnias</LastName>
            <ForeName>Ilias</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0003-1188-529X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kontos</LastName>
            <ForeName>Christos K</ForeName>
            <Initials>CK</Initials>
            <Identifier Source="ORCID">0000-0002-9935-8461</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anastasakis</LastName>
            <ForeName>Dimitrios</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Institute of Musculoskeletal and Arthritis and Skin, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Korfiati</LastName>
            <ForeName>Aigli</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Physics, School of Medicine, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kyriakopoulos</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-5628-6138</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Theofilatos</LastName>
            <ForeName>Konstantinos</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>InSyBio Ltd,19 Staple Gardens SO23 8SR, Winchester, Hampshire, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mavroudi</LastName>
            <ForeName>Seferina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>InSyBio Ltd,19 Staple Gardens SO23 8SR, Winchester, Hampshire, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Magoulas</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papaioannou</LastName>
            <ForeName>Dionissios</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, University of Patras, Patras, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scorilas</LastName>
            <ForeName>Andreas</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stathopoulos</LastName>
            <ForeName>Constantinos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece. cstath@med.upatras.gr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drainas</LastName>
            <ForeName>Denis</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, School of Medicine, University of Patras, Patras, Greece. drainas@med.upatras.gr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Pharmacogenomics J</MedlineTA>
        <NlmUniqueID>101083949</NlmUniqueID>
        <ISSNLinking>1470-269X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C581546">N1,N12-bis(retinoyl)spermine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2FZ7Y3VOQX</RegistryNumber>
          <NameOfSubstance UI="D013096">Spermine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5688UTC01R</RegistryNumber>
          <NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000084282" MajorTopicYN="N">HaCaT Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013096" MajorTopicYN="N">Spermine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34145402</ArticleId>
        <ArticleId IdType="doi">10.1038/s41397-021-00241-9</ArticleId>
        <ArticleId IdType="pii">10.1038/s41397-021-00241-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Beckenbach L, Baron JM, Merk HF, Löffler H, Amann PM. Retinoid treatment of skin diseases. Eur J Dermatol. 2015;25:384–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26069148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estler M, Boskovic G, Denvir J, Miles S, Primerano DA, Niles RM. Global analysis of gene expression changes during retinoic acid-induced growth arrest and differentiation of melanoma: comparison to differentially expressed genes in melanocytes vs melanoma. BMC Genomics. 2008;9:478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18847503</ArticleId>
            <ArticleId IdType="pmc">2572629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szymański Ł, Skopek R, Palusińska M, Schenk T, Stengel S, Lewicki S, et al. Retinoic acid and its derivatives in skin. Cells. 2020;9:2660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">7764495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira R, Napoli J, Enver T, Bernardino L, Ferreira L. Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine. Nat Commun. 2020;11:4265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32848154</ArticleId>
            <ArticleId IdType="pmc">7450074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoop VM, Fusenig NE, Mirancea N. Epidermal organization and differentiation of HaCaT keratinocytes in organotypic coculture with human dermal fibroblasts. J Invest Dermatol. 1999;112:343–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10084313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breitkreutz D, Stark H-J, Plein P, Baur M, Fusenig NE. Differential modulation of epidermal keratinization in immortalized (HaCaT) and tumorigenic human skin keratinocytes (HaCaT-ras) by retinoic acid and extracellular Ca2+. Differentiation. 1993;54:201–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7505755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang X-H, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol Mech Dis. 2011;6:345–64.</Citation>
        </Reference>
        <Reference>
          <Citation>Hu XT, Zuckerman KS. Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells. Cell Prolif. 2014;47:200–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24646031</ArticleId>
            <ArticleId IdType="pmc">6496847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3165295</ArticleId>
            <ArticleId IdType="pmc">3165295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin E, Chen M-C, Huang C-Y, Hsu S-L, Huang WJ, Lin M-S, et al. All-trans retinoic acid induces DU145 cell cycle arrest through Cdk5 activation. Cell Physiol Biochem. 2014;33:1620–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24851929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M-l, Tao Y, Zhou W-Q, Ma P-C, Cao Y-P, He C-D, et al. All- trans retinoic acid induces cell-cycle arrest in human cutaneous squamous carcinoma cells by inhibiting the mitogen-activated protein kinase-activated protein 1 pathway. Clin Exp Dermatol. 2014;39:354–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24635079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schenk T, Stengel S, Zelent A. Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer. 2014;111:2039–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25412233</ArticleId>
            <ArticleId IdType="pmc">4260020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Qassab Y, Grassilli S, Brugnoli F, Vezzali F, Capitani S, Bertagnolo V. Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells. BMC Cancer. 2018;18:1194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30497437</ArticleId>
            <ArticleId IdType="pmc">6267073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, et al. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteom. 2005;4:205–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Amoutzias GD, Pichler EE, Mian N, De Graaf D, Imsiridou A, Robinson-Rechavi M, et al. A protein interaction atlas for the nuclear receptors: properties and quality of a hub-based dimerisation network. BMC Syst Biol. 2007;1:34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17672894</ArticleId>
            <ArticleId IdType="pmc">1971058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Browne H, Mason G, Tang T. Retinoids and pregnancy: an update. Obstet Gynaecol. 2014;16:7–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Ni X, Hu G, Cai X. The success and the challenge of all-trans retinoic acid in the treatment of cancer. Crit Rev Food Sci Nutr. 2019;59:S71–S80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30277803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magoulas G, Papaioannou D, Papadimou E, Drainas D. Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity. Eur J Med Chem. 2009;44:2689–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19216007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vourtsis D, Lamprou M, Sadikoglou E, Giannou A, Theodorakopoulou O, Sarrou E, et al. Effect of an all-trans-retinoic acid conjugate with spermine on viability of human prostate cancer and endothelial cells in vitro and angiogenesis in vivo. Eur J Pharm. 2013;698:122–30.</Citation>
        </Reference>
        <Reference>
          <Citation>Hadjipavlou-Litina D, Magoulas GE, Bariamis SE, Drainas D, Avgoustakis K, Papaioannou D. Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential? Bioorg Med Chem. 2010;18:8204–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21041094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petridis T, Giannakopoulou D, Stamatopoulou V, Grafanaki K, Kostopoulos CG, Papadaki H, et al. Investigation on toxicity and teratogenicity in rats of a retinoid-polyamine conjugate with potent anti-inflammatory properties. Birth Defects Res Part B Dev Reprod Toxicol. 2016;107:32–44.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee D-D, Stojadinovic O, Krzyzanowska A, Vouthounis C, Blumenberg M, Tomic-Canic M. Retinoid-responsive transcriptional changes in epidermal keratinocytes. J Cell Physiol. 2009;220:427–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19388012</ArticleId>
            <ArticleId IdType="pmc">4386731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima L, de Melo TCT, Marques D, de Araújo JNG, Leite ISF, Alves CX, et al. Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review. BMC Cancer. 2019;19:866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31470825</ArticleId>
            <ArticleId IdType="pmc">6717326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gholikhani-Darbroud R. MicroRNA and retinoic acid. Clin Chim Acta. 2020;502:15–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31812758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bariamis SE, Magoulas GE, Grafanaki K, Pontiki E, Tsegenidis T, Athanassopoulos CM, et al. Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids. Bioorg Med Chem. 2015;23:7251–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26515039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skeparnias I, Anastasakis D, Grafanaki K, Kyriakopoulos G, Alexopoulos P, Dougenis D, et al. Contribution of miRNAs, tRNAs and tRFs to aberrant signaling and translation deregulation in lung cancer. Cancers. 2020;12:3056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">7593945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theofilatos K, Dimitrakopoulos C, Likothanassis S, Kleftogiannis D, Moschopoulos C, Alexakos C, et al. The human interactome knowledge base (HINT-KB): an integrative human protein interaction database enriched with predicted protein–protein interaction scores using a novel hybrid technique. Artif Intell Rev. 2014;42:427–43.</Citation>
        </Reference>
        <Reference>
          <Citation>Shannon P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14597658</ArticleId>
            <ArticleId IdType="pmc">14597658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Li D, Tang Y, Wu F, Wang J. CytoCluster: a cytoscape plugin for cluster analysis and vsualization of biological networks. Int J Mol Sci. 2017;18:1880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">5618529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang D. Tanshinol inhibits growth of malignant melanoma cells via regulating miR-1207-5p/CHPF pathway. Arch Dermatol Res. 2020;312:373–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31828417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singhvi G, Manchanda P, Krishna Rapalli V, Kumar Dubey S, Gupta G, Dua K. MicroRNAs as biological regulators in skin disorders. Biomed Pharmacother. 2018;108:996–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30372911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillespie J, Skeeles LE, Allain DC, Kent MN, Peters SB, Nagarajan P, et al. MicroRNA expression profiling in metastatic cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2016;30:1043–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25764000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang M, Yuan W, Zhang W, Huang J. Expression of miR-490-5p, miR-148a-3p and miR-608 in bladder cancer and their effects on the biological characteristics of bladder cancer cells. Oncol Lett. 2019;17:4437–42.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang J, Zhu Z, Sheng J, Yu Z, Yao B, Huang K, et al. miR-509-3-5P inhibits the invasion and lymphatic metastasis by targeting PODXL and serves as a novel prognostic indicator for gastric cancer. Oncotarget. 2017;8:34867–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28432273</ArticleId>
            <ArticleId IdType="pmc">5471018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Lü M-H, Zhang D, Hao N-B, Fan Y-H, Wu Y-Y, et al. miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis. 2014;5:e1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24481448</ArticleId>
            <ArticleId IdType="pmc">4040688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Wu P, Tang Y, Fan Y, Liu Y, Fang X, et al. Down-regulation of MiR-181c-5p promotes epithelial-to-mesenchymal transition in laryngeal squamous cell carcinoma via targeting SERPINE1. Front Oncol. 2020;10:544476</Citation>
        </Reference>
        <Reference>
          <Citation>Jin Z, Jia B, Tan L, Liu Y. miR-330-3p suppresses liver cancer cell migration by targeting MAP2K1. Oncol Lett. 2019;18:314–20.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang H, Liu G, Li T, Wang N, Wu J, Zhi H. MiR-330-3p functions as a tumor suppressor that regulates glioma cell proliferation and migration by targeting CELF1. Arch Med Sci. 2020;16:1166–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32864006</ArticleId>
            <ArticleId IdType="pmc">7444697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Huang R, Wang L, Hao J, Zhang Q, Ling R, et al. microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression. Cell Prolif. 2015;48:643–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26597380</ArticleId>
            <ArticleId IdType="pmc">6496530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dever TE, Ivanov IP. Roles of polyamines in translation. J Biol Chem. 2018;293:18719–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30323064</ArticleId>
            <ArticleId IdType="pmc">6290161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishida S, Shigemoto-Mogami Y, Shinozaki Y, Kagechika H, Shudo K, Ozawa S, et al. Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharm. 2004;68:2177–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15498508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Liu D, Hu Z, Luo C, Zheng SL. miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6. Onco Targets Ther. 2019;12:835–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30774371</ArticleId>
            <ArticleId IdType="pmc">6355169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You W, Zhang X, Ji M, Yu Y, Chen C, Xiong Y, et al. MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells. Int J Biol Sci. 2018;14:644–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29904279</ArticleId>
            <ArticleId IdType="pmc">6001653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao Y, Li Q, Sun G, Wang L, Zhang D, Xu H, et al. MiR‐5683 suppresses glycolysis and proliferation through targeting pyruvate dehydrogenase kinase 4 in gastric cancer. Cancer Med. 2020;9:7231–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32780563</ArticleId>
            <ArticleId IdType="pmc">7541129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayub SG, Kaul D, Ayub T. An androgen-regulated miR-2909 modulates TGFβ signalling through AR/miR-2909 axis in prostate cancer. Gene. 2017;631:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28754634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Li J, Ren J, Zhang D. MicroRNA-485-5p represses melanoma cell invasion and proliferation by suppressing Frizzled7. Biomed Pharmacother. 2017;90:303–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28364602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Cheng Z, Pan F, Yan W. MicroRNA-373 promotes growth and cellular invasion in osteosarcoma cells by activation of the PI3K/AKT‐Rac1‐JNK pathway: the potential role in spinal osteosarcoma. Oncol Res Featur Preclin Clin Cancer Ther. 2017;25:989–99.</Citation>
        </Reference>
        <Reference>
          <Citation>Bai X, Yang M, Xu Y. MicroRNA-373 promotes cell migration via targeting salt-inducible kinase 1 expression in melanoma. Exp Ther Med. 2018;16:4759–64.</Citation>
        </Reference>
        <Reference>
          <Citation>Hong S, Yan Z, Wang H, Ding L, Song Y, Bi M. miR-663b promotes colorectal cancer progression by activating Ras/Raf signaling through downregulation of TNK1. Hum Cell. 2020;33:104–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31758392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y, Yang L, Qin A, Qiao Z, Huang B, Jiang X, et al. miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma. Biochem Biophys Res Commun. 2020;522:716–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31791584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miskin RP, Warren JSA, Ndoye A, Wu L, Lamar JM, DiPersio CM. Integrin α3β1 promotes invasive and metastatic properties of breast cancer cells through induction of the Brn-2 transcription factor. Cancers. 2021;13:480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33513758</ArticleId>
            <ArticleId IdType="pmc">7866210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song J, Zhang J, Wang J, Wang J, Guo X, Dong W. β1 integrin mediates colorectal cancer cell proliferation and migration through regulation of the Hedgehog pathway. Tumor Biol. 2015;36:2013–21.</Citation>
        </Reference>
        <Reference>
          <Citation>Trojanowicz B, Winkler A, Hammje K, Chen Z, Sekulla C, Glanz D, et al. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. J Mol Endocrinol. 2009;42:249–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19060179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998;75:246–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9462715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratzinger S, Grässel S, Dowejko A, Reichert TE, Bauer RJ. Induction of type XVI collagen expression facilitates proliferation of oral cancer cells. Matrix Biol. 2011;30:118–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21251976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao H-S, Sun C, Li X-X, Wang Y, Jin K-Z, Zhang X-P, et al. Annexin A4-nuclear factor-κB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer. Sci Rep. 2016;6:31056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27491820</ArticleId>
            <ArticleId IdType="pmc">4974512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elias I, Ferré T, Vilà L, Muñoz S, Casellas A, Garcia M, et al. ALOX5AP overexpression in adipose tissue leads to LXA 4 production and protection against diet-induced obesity and insulin resistance. Diabetes. 2016;65:2139–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27207555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverbush D, Sharan R. A systematic approach to orient the human protein–protein interaction network. Nat Commun. 2019;10:3015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31289271</ArticleId>
            <ArticleId IdType="pmc">6617457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardinez C, Miraghazadeh B, Tanita K, da Silva E, Hoshino A, Okada S, et al. Gain-of-function IKBKB mutation causes human combined immune deficiency. J Exp Med. 2018;215:2715–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30337470</ArticleId>
            <ArticleId IdType="pmc">6219745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tetel MJ, Acharya KD. Nuclear receptor coactivators: regulators of steroid action in brain and behaviour. J Neuroendocrinol. 2013;25:1209–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23795583</ArticleId>
            <ArticleId IdType="pmc">3830605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiley JW, Higgins GA, Athey BD. Stress and glucocorticoid receptor transcriptional programming in time and space: Implications for the brain-gut axis. Neurogastroenterol Motil. 2016;28:12–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26690871</ArticleId>
            <ArticleId IdType="pmc">4688904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korashy H, Abuohashish H, Maayah Z. The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma. Curr Pharm Des. 2013;19:7155–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23909806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James Faresse N, Canella D, Praz V, Michaud J, Romascano D, Hernandez N. Genomic study of RNA polymerase II and III SNAPc-bound promoters reveals a gene transcribed by both enzymes and a broad use of common activators. PLoS Genet. 2012;8:e1003028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23166507</ArticleId>
            <ArticleId IdType="pmc">3499247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grafanaki K, Anastasakis D, Kyriakopoulos G, Skeparnias I, Georgiou S, Stathopoulos C. Translation regulation in skin cancer from a tRNA point of view. Epigenomics. 2019;11:215–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30565492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haase M, Fitze G. HSP90AB1: helping the good and the bad. Gene. 2016;575:171–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26358502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parruti G, Peracchia F, Sallese M, Ambrosini G, Masini M, Rotilio D, et al. Molecular analysis of human beta-arrestin-1: cloning, tissue distribution, and regulation of expression. Identification of two isoforms generated by alternative splicing. J Biol Chem. 1993;268:9753–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8486659</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
